A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease

A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease

Abstract Background In chronic obstructive pulmonary disease (COPD) patients, combination treatment with long-acting muscarinic antagonist (LAMA) and long-acting β2 agonist (LABA) increases forced expiratory volume in one second and reduces symptoms compared to monotherapy. In Japan, three different...

Full description

Bibliographic Details
Main Authors: Masato Muraki, Yuki Kunita, Ken Shirahase, Ryo Yamazaki, Soichiro Hanada, Hirochiyo Sawaguchi, Yuji Tohda
Format: Article
Language:English
Published: BMC 2021-01-01
Series:BMC Pulmonary Medicine
Subjects:
Glycopyrronium/indacaterol
Umeclidinium/vilanterol
Tiotropium/olodaterol
Quality of life
Inhaler device
COPD
Online Access:https://doi.org/10.1186/s12890-021-01403-y

Internet

https://doi.org/10.1186/s12890-021-01403-y

Similar Items